Results 241 to 250 of about 12,005,894 (331)

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Usefulness of a New Effective Dose Conversion Factor Using Size-Specific Dose Estimate (SSDE) in Abdominopelvic Region. [PDF]

Cureus
Takanashi M, Katada Y, Kuroda I, Hoshina M, Matsushita M, Masuda K, Sugahara S.   +6 more
europepmc   +1 more source

Dose-effect relationships [PDF]

Annals of the ICRP, 1980
openaire   +1 more source

Figure 3 Highly effective fibrinolysis by a sequential synergistic combination of mini-dose tPA plus low-dose mutant proUK

, 2015
Victor Gurewich
openalex   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Comparison of the effective dose of alfentanil for percutaneous thermal ablation in subcapsular versus non-subcapsular hepatocellular carcinoma: a prospective dose-finding study utilizing the up-and-down sequential allocation method. [PDF]

BMC Anesthesiol
Xiao S, Qiu D, Zhang W, Cai S.
europepmc   +1 more source

PROTON THERAPY REDUCES THE EFFECTIVE DOSE TO IMMUNE CELLS (EDIC) IN BREAST CANCER PATIENTS

Pierre Loap, Jérémi Vu-Bezin, Ludovic De Marzi, Youlia Kirova   +3 more
openalex   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Minimum effective dose of betamethasone for incisional local infiltration for the prevention of postoperative pain after spine surgery: study protocol for a randomised controlled trial. [PDF]

BMJ Open
Wang Y, Han B, Zhao C, Ren H, Jia W, Luo F.   +5 more
europepmc   +1 more source

CT Scan Effective Radiation Dose Reduction in Pediatric Trauma Patients

, 2021
Benjamin Clouse, Elizabeth H. Ey, Sara Paton, Frank Pianki, Jeffrey C. Pence, Lisa Schwing, Melody G. Campbell   +6 more
openalex   +1 more source